Six hours after administration, the fluorescence intensity at the tumor site in the Tf-LP-ERN-DiR nanoparticle treatment group was higher than that in the LP-ERN-DiR nanoparticle treatment group, which indicated that Tf enhanced the tumor-targeting ability of the nanoparticle drug-delivery system (Figure 4A). The gene discussed is TF; the disease is neoplasm.